Mayo Clinic: Breast Carcinoma In Situ trials

The registry lists 12 Breast Carcinoma In Situ studies with Mayo Clinic as lead sponsor. 3 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 5No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone LossRecruitingNCT07044310Phase 2
• Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor TherapyRecruitingNCT06401889
• Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and ReconstructionRecruitingNCT06153836Phase 2
• Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskTerminatedNCT04570956Phase 2Results posted
• Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)CompletedNCT06106282
• Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic WomenTerminatedNCT05755269
• Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer SurvivorsCompletedNCT04999826
• Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast CancerCompletedNCT04693338Phase 1
• Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast CancerCompletedNCT04535323Phase 1
• Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerTerminatedNCT03979508Phase 2
• Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal AtrophyWithdrawnNCT03666819Phase 2
• Molecular Breast Imaging in Women With Atypia and LCISCompletedNCT00620087Not applicable